Skip to main content
TipRanks
Go Ultimate75% OFF

Medico Remedies Ltd. (MEDICO) AI Stock Analysis

0 Followers
IN:MEDICO

Medico Remedies Ltd.

(NSE:MEDICO)

Select Model
Rating:61Neutral
Price Target:INR 20.00â–²(6.78% Upside)
Action:reiterated
Date:09/29/26

The score reflects a growing and increasingly profitable business backed by a strengthening balance sheet, offset by very weak, volatile cash flows and a pronounced bearish price trend that leave execution and funding risks elevated; the moderate valuation offers some balance but does not fully counter these cash flow and technical headwinds.

Positive Factors
Revenue and earnings growthConsistent revenue expansion, together with a substantial rise in net income, indicates stronger commercial scale and improving earnings power. If this trajectory persists, Medico can build a larger operating base and reinvest in growth over the next several quarters.
Negative Factors
Weak cash conversionThe gap between improving accounting profit and sharply weaker operating cash flow raises concerns about earnings quality and working-capital demands. Negative free cash flow may limit internally funded expansion and could increase dependence on borrowing if the pattern persists.

Medico Remedies Ltd. (MEDICO) vs. iShares MSCI India ETF (INDA)

-70%-60%-50%-40%-30%-20%-10%0%10%IN:MEDICO-63.34%INDA-5.15%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.55B
Dividend Yield
―
Average Volume (3M)
30.65K
Price to Earnings (P/E)
11.3
Beta (1Y)
0.21
Revenue Growth
50.78%
EPS Growth
20.08%
Country
India
Employees
105
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Medico Remedies Ltd. Business Overview & Revenue Model

Company Description

Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. Its product portfolio includes general formulations, which consists of general tablets, capsules, and dry syrups; and beta lactum formulations, which co...

Medico Remedies Ltd. Financial Statement Overview

Summary

Solid revenue and earnings growth supported by a strengthening, moderately leveraged balance sheet, but very weak and volatile cash generation with negative free cash flow materially tempers the overall financial quality.

Income Statement

79Positive

Balance Sheet

82Very Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.38B2.06B1.51B1.45B1.40B1.21B
Gross Profit496.22M445.57M426.11M175.25M355.66M176.65M
EBITDA221.00M229.60M150.03M148.57M135.66M74.34M
Net Income138.15M131.15M100.93M82.91M72.42M48.12M
Balance Sheet
Total Assets01.53B1.20B961.95M874.48M774.04M
Cash, Cash Equivalents and Short-Term Investments37.51M37.51M25.45M15.46M21.95M23.40M
Total Debt0192.04M147.00M80.50M97.62M125.97M
Total Liabilities-754.75M779.29M573.30M438.24M436.05M408.30M
Stockholders Equity754.75M754.75M624.69M523.71M438.43M373.20M
Cash Flow
Free Cash Flow-5.86M-34.84M17.07M2.04M15.75M-11.50M
Operating Cash Flow6.43M10.06M48.92M24.38M81.67M58.62M
Investing Cash Flow-12.01M-46.47M-34.60M-26.77M-66.03M-17.56M
Financing Cash Flow-2.70M44.53M-5.20M-4.90M-18.17M-57.71M

Medico Remedies Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price18.73

Price Trends

50DMA25.30Negative
100DMA33.76Negative
200DMA38.51Negative

Market Momentum

MACD-1.81Negative
RSI30.84Neutral
STOCH28.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Negative. The current price of 18.73 is below the 20-day moving average (MA) of 19.29, below the 50-day MA of 25.30, and below the 200-day MA of 38.51, indicating a bearish trend. The MACD of -1.81 indicates Negative momentum. The RSI at 30.84 is Neutral, neither overbought nor oversold. The STOCH value of 28.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICO.

Medico Remedies Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:MEDICO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:MEDICAMEQIN:MEDICAMEQ64NeutralINR 3.99B32.55―0.34%27.47%6.56%
IN:MEDICOIN:MEDICO61NeutralINR 1.55B11.25――50.78%20.08%
IN:BAFNAPHIN:BAFNAPH60NeutralINR 11.36B98.77――8.74%31.20%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALBERTDAVDIN:ALBERTDAVD54NeutralINR 4.39B15.26―0.64%19.69%―
IN:ZIMLABIN:ZIMLAB53NeutralINR 7.29B256.58――13.14%-60.77%
IN:VALIANTLABIN:VALIANTLAB42NeutralINR 5.61B33.76――102.37%176.45%

* General Sector Average

Performance Comparison

0%100%IN:MEDICOIN:ALBERTDAVDIN:BAFNAPHIN:MEDICAMEQIN:VALIANTLABIN:ZIMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:MEDICO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:MEDICOMedico Remedies Ltd.18.73-32.22-63.24%
IN:ALBERTDAVDAlbert David Ltd770.00-34.40-4.28%
IN:BAFNAPHBafna Pharmaceuticals Limited480.00309.15180.95%
IN:MEDICAMEQMedicamen Biotech Limited293.85-109.78-27.20%
IN:VALIANTLABValiant Laboratories Ltd.103.2526.0533.74%
IN:ZIMLABZim Laboratories Ltd.135.8562.8486.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026